Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. (June 2010)

• Record Type: Journal Article
• Authors: Achaval, Sofia de; Suarez-Almazor, Maria E
• Is Part Of: International journal of clinical rheumatology. Volume 5:Number 3(2010)
• Page Start: 313
• Page End: 326
• Publication Date: 2010-06
• Subjects: adherence -- disease-modifying antirheumatic drugs -- rheumatoid arthritis -- systematic review -- systemic lupus erythematosus; Rheumatology -- Periodicals; 616.723005
• DOI: 10.2217/ijr.10.15
• Languages: English
• ISSNs: 1758-4272

Abstract

Treatment adherence is critical in the management of rheumatic diseases. Recent advances in therapy for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are promising, although the impact on quality of life may be limited due to nonadherence. Databases including Ovid Medline, Scopus and the Epub-ahead-of-print subset of PubMed were searched for the period of the last 10 years using combined keywords patient compliance, medication adherence, disease modifying antirheumatic drug (DMARD), rheumatoid arthritis and systemic lupus erythematosus. Additional references from retrieved papers were considered. Inclusion criteria were the following: identification of a quantitative measure of adherence to medications including DMARDs and biologics; inclusion of well-defined measures of adherence; and patients with RA or SLE. Studies in RA and SLE patients demonstrated overall inadequate treatment adherence. Adherence was measured using multiple methods including pharmacy records, electronic monitoring, self-report and physician report. The evidence for interventions to improve treatment adherence was limited and demonstrated various results. Future research should further explore determinants of nonadherence and continue to examine the efficacy of implementing various strategies to improve medication management in this patient population.